NEW YORK, NY / ACCESSWIRE / October 6, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Nano-X Imaging Ltd. (NASDAQ:NNOX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/nano-x-imaging-ltd-loss-submission-form?prid=9863&wire=1
Lead Plaintiff Deadline: November 16, 2020
Class Period: August 21, 2020 - September 15, 2020
Allegations against NNOX include that: (1) Nano-X's commercial agreements and its customers were fabricated; (2) Nano-X's statements regarding its "novel" Nanox System were misleading as the Company never provided data comparing its images with images from competitors' machines; (3) Nano-X's submission to the U.S. Food and Drug Administration admitted the Nanox System was not original; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Golar LNG Limited (NASDAQ:GLNG)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/golar-lng-limited-loss-submission-form?prid=9863&wire=1
Lead Plaintiff Deadline: November 23, 2020
Class Period: April 30, 2020 - September 24, 2020
Allegations against GLNG include that: (1) certain employees, including the Chief Executive Officer of Hygo Energy Transition Ltd. f/k/a Golar Power Limited ("Hygo"), had bribed third parties, thereby violating anti-bribery policies; (2) as a result, the Company was likely to face regulatory scrutiny and possible penalties; (3) as a result of the foregoing reputational harm, Hygo's valuation ahead of its initial public offering would be significantly impaired; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=9863&wire=1
Lead Plaintiff Deadline: November 24, 2020
Class Period: February 28, 2020 - August 18, 2020
Allegations against BMRN include that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong